Atomera (ATOM) 10-Q 30 Jul 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2024	Jul. 30, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-37850
Entity Registrant Name	ATOMERA INC
Entity Central Index Key	0001420520
Entity Tax Identification Number	30-0509586
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	750 University Avenue
Entity Address, Address Line Two	Suite 280
Entity Address, City or Town	Los Gatos
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95032
City Area Code	408
Local Phone Number	442-5248
Title of 12(b) Security	Common stock: Par value $0.001
Trading Symbol	ATOM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,804,438

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 14,484	$ 12,591
Short-term investments	3,804	6,940
Accounts receivable	6	0
Unbilled contracts receivable	0	550
Interest receivable	74	79
Prepaid expenses and other current assets	578	244
Total current assets	18,946	20,404
Property and equipment, net	75	100
Long-term prepaid maintenance and supplies	91	91
Security deposit	14	14
Operating lease right-of-use asset	401	517
Financing lease right-of-use-asset	2,341	2,903
Total assets	21,868	24,029
Current liabilities:
Accounts payable	646	618
Accrued expenses	249	222
Accrued payroll related expenses	594	1,382
Current operating lease liability	256	264
Current financing lease liability	1,386	1,328
Deferred revenue	13	0
Total current liabilities	3,144	3,814
Long-term operating lease liability	137	295
Long-term financing lease liability	1,108	1,750
Total liabilities	4,389	5,859
Commitments and contingencies (see Note 9)
Stockholders’ equity:
Preferred stock $0.001 par value, authorized 2,500 shares; none issued and outstanding as of June 30, 2024 and December 31, 2023	0	0
Common stock: $0.001 par value, authorized 47,500 shares; 27,622 shares issued and 27,610 outstanding as of June 30, 2024; and 26,107 shares issued and outstanding as of December 31, 2023	28	26
Additional paid in capital	229,726	221,229
Other comprehensive income (loss)	(7)	0
Accumulated deficit	(212,268)	(203,085)
Total stockholders’ equity	17,479	18,170
Total liabilities and stockholders’ equity	$ 21,868	$ 24,029

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,500	2,500
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	47,500	47,500
Common stock, shares issued	27,622	26,107
Common stock, shares outstanding	27,610	26,107

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	$ 72	$ 0	$ 90	$ 0
Cost of revenue	(74)	0	(107)	0
Gross margin	(2)	0	(17)	0
Operating expenses
Research and development	2,589	3,192	5,447	6,228
General and administrative	1,832	1,775	3,643	3,517
Selling and marketing	207	393	557	782
Total operating expenses	4,628	5,360	9,647	10,527
Loss from operations	(4,630)	(5,360)	(9,664)	(10,527)
Other income (expense)
Interest income	185	152	390	351
Accretion income	47	107	93	109
Interest expense	(35)	(51)	(74)	(104)
Other income, net	72	0	72	0
Total other income (expense), net	269	208	481	356
Net loss	$ (4,361)	$ (5,152)	$ (9,183)	$ (10,171)
Net loss per common share, basic	$ (0.16)	$ (0.21)	$ (0.35)	$ (0.42)
Net loss per common share, diluted	$ (0.16)	$ (0.21)	$ (0.35)	$ (0.42)
Weighted average number of common shares outstanding, basic	26,467	24,677	26,253	24,171
Weighted average number of common shares outstanding, diluted	26,467	24,677	26,253	24,171

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net loss	$ (4,361)	$ (5,152)	$ (9,183)	$ (10,171)
Unrealized gain (loss) on available-for-sale securities	(6)	0	(7)	(2)
Net loss	$ (4,367)	$ (5,152)	$ (9,190)	$ (10,173)

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2022	$ 24	$ 203,585		$ (183,295)	$ 20,314
Beginning balance, shares at Dec. 31, 2022	23,973
Stock-based compensation		927			927
Stock-based compensation, shares	297
Stock option exercise		39			39
Stock option exercise, shares	10
At-the-market sale of stock, net of commissions and expenses		274			274
At-the-market sale of stock, net of commissions and expenses, shares	50
Net loss				(5,019)	(5,019)
Unrealized gain (loss) on available-for-sale securities			(2)		(2)
Ending balance, value at Mar. 31, 2023	$ 24	204,825	(2)	(188,314)	16,533
Ending balance, shares at Mar. 31, 2023	24,330
Beginning balance, value at Dec. 31, 2022	$ 24	203,585		(183,295)	20,314
Beginning balance, shares at Dec. 31, 2022	23,973
Net loss					(10,171)
Unrealized gain (loss) on available-for-sale securities					(2)
Ending balance, value at Jun. 30, 2023	$ 26	216,681	(2)	(193,466)	23,239
Ending balance, shares at Jun. 30, 2023	25,770
Beginning balance, value at Mar. 31, 2023	$ 24	204,825	(2)	(188,314)	16,533
Beginning balance, shares at Mar. 31, 2023	24,330
Stock-based compensation		1,030			1,030
Stock-based compensation, shares	60
Stock option exercise		39			39
Stock option exercise, shares	10
At-the-market sale of stock, net of commissions and expenses	$ 2	10,787			10,789
At-the-market sale of stock, net of commissions and expenses, shares	1,370
Net loss				(5,152)	(5,152)
Unrealized gain (loss) on available-for-sale securities					0
Ending balance, value at Jun. 30, 2023	$ 26	216,681	(2)	(193,466)	23,239
Ending balance, shares at Jun. 30, 2023	25,770
Beginning balance, value at Dec. 31, 2023	$ 26	221,229		(203,085)	18,170
Beginning balance, shares at Dec. 31, 2023	26,107
Stock-based compensation		1,024			1,024
Stock-based compensation, shares	275
Stock option exercise		86			86
Stock option exercise, shares	13
Forfeiture of restricted stock issuance
Forfeiture of restricted stock issuance, shares	(20)
At-the-market sale of stock, net of commissions and expenses	$ 1	3,949			3,950
At-the-market sale of stock, net of commissions and expenses, shares	510
Net loss				(4,822)	(4,822)
Unrealized gain (loss) on available-for-sale securities			(1)		(1)
Ending balance, value at Mar. 31, 2024	$ 27	226,288	(1)	(207,907)	18,407
Ending balance, shares at Mar. 31, 2024	26,885
Beginning balance, value at Dec. 31, 2023	$ 26	221,229		(203,085)	18,170
Beginning balance, shares at Dec. 31, 2023	26,107
Net loss					(9,183)
Unrealized gain (loss) on available-for-sale securities					(7)
Ending balance, value at Jun. 30, 2024	$ 28	229,726	(7)	(212,268)	17,479
Ending balance, shares at Jun. 30, 2024	27,610
Beginning balance, value at Mar. 31, 2024	$ 27	226,288	(1)	(207,907)	18,407
Beginning balance, shares at Mar. 31, 2024	26,885
Stock-based compensation		987			987
Stock-based compensation, shares	65
Forfeiture of restricted stock issuance
Forfeiture of restricted stock issuance, shares	(11)
At-the-market sale of stock, net of commissions and expenses	$ 1	2,441			2,442
At-the-market sale of stock, net of commissions and expenses, shares	669
Other sale		10			10
Other sale, shares	2
Net loss				(4,361)	(4,361)
Unrealized gain (loss) on available-for-sale securities			(6)		(6)
Ending balance, value at Jun. 30, 2024	$ 28	$ 229,726	$ (7)	$ (212,268)	$ 17,479
Ending balance, shares at Jun. 30, 2024	27,610

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (9,183)	$ (10,171)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	30	40
Operating lease right of use asset amortization	116	102
Financing lease right of use asset amortization	562	581
Stock-based compensation	2,011	1,957
Change in unrealized gain (loss) on cash equivalents	(1)
Net accretion of discounts on available-for-sale securities	(87)	(89)
Changes in operating assets and liabilities:
Accounts receivable	(6)	0
Unbilled contracts receivable	550	0
Interest receivable	14	(42)
Prepaid and other current assets	(335)	(232)
Accounts payable	(70)	165
Accrued expenses	27	45
Accrued payroll expenses	(788)	(389)
Operating lease liability	(166)	(139)
Deferred revenue	13	0
Net cash used in operating activities	(7,313)	(8,172)
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of property and equipment	(6)	(18)
Purchase of available-for-sale securities	(4,290)	(10,853)
Maturity of available-for-sale securities	7,500	0
Net cash provided by/(used in) investing activities	3,204	(10,871)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from at-the-market sale of stock, net of commissions and expenses	6,392	11,063
Proceeds from exercise of stock options	86	78
Proceeds from stock sale	10	0
Payments on principal of financing lease	(486)	(378)
Net cash provided by financing activities	6,002	10,763
Net increase/(decrease) in cash and cash equivalents	1,893	(8,280)
Cash and cash equivalents at beginning of period	12,591	21,184
Cash and cash equivalents at end of period	14,484	12,904
Supplemental information:
Cash paid for interest	63	104
Cash paid for taxes	$ 0	$ 0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (4,361)	$ (4,822)	$ (5,152)	$ (5,019)	$ (9,183)	$ (10,171)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS Atomera Incorporated (“Atomera” or the “Company”) was incorporated in the state of Delaware in March 2007 under the name MEARS Technologies, Inc. and is engaged in the development, commercialization and licensing of proprietary processes and technologies for the semiconductor industry. On January 12, 2016, the Company changed its name to Atomera Incorporated. Atomera is an early-stage company, having only limited revenue-generating activities, and is devoting substantially all its efforts toward technology research and development and to commercially licensing its technology to designers and manufacturers of integrated circuits.

LIQUIDITY AND MANAGEMENT PLANS

LIQUIDITY AND MANAGEMENT PLANS	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND MANAGEMENT PLANS	2. LIQUIDITY AND MANAGEMENT PLANS At June 30, 2024, the Company had cash, cash equivalents and short-term investments of approximately $ 18.3 million 15.8 million On May 31, 2022, Atomera entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc. and Craig-Hallum Capital Group LLC, as agents, under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock, in “at the market” offerings to or through the agents, having aggregate offering proceeds of up to $50.0 million (the “ATM Facility”). During the three-month period ended June 30, 2024, the Company sold approximately 669,000 3.82 2.4 million 1.2 million 5.66 6.4 million 23.1 million Based on the funds it has available as of the date of the filing of this report, the Company believes that it has sufficient capital to fund its current business plans and obligations over, at least, 12 months from the date that these financial statements have been issued. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its technology, competing technological and market developments, and the need to enter into collaborations with other companies or acquire technologies to enhance or complement its current offerings.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 15, 2024. Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the three and six months ended June 30, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and its results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2023 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC on February 15, 2024. These unaudited condensed financial statements should be read in conjunction with that report. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. Cash equivalents may be invested in money market funds or U.S. agency bonds. Cash and cash equivalents are carried at cost, which approximates their fair value. The Company's portfolio of short-term investments is comprised solely of U.S. treasury bills and agency bonds with maturities of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity requirements. These debt securities are classified as current assets in the condensed balance sheet and recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss). Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are reported in other income, net in the condensed statements of operations when incurred. Unrealized gains and losses are included in other comprehensive income (loss) on the condensed balance sheets. Recent Accounting Standards From time to time, new accounting standards are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. No new accounting standards issued or effective during the period ended June 30, 2024 have had or are expected to have a significant impact on the Company’s financial statements.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	4. FAIR VALUE MEASUREMENTS Accounting Standards Codification (“ASC”) 820, Fair Value Measurements Level 1 — Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s cash equivalents and short-term investments were measured at fair value on a recurring basis as Level 1 assets. The Company’s cash, cash equivalents and short-term investments classified by security type as of June 30, 2024 and December 31, 2023 consisted of the following (in thousands): Schedule of fair value measurements June 30, 2024 Cost Unrealized Gain/(Loss) Accretion of Discount Fair Value Cash $ 86 $ – $ – $ 86 Money market funds 11,368 – – 11,368 US treasury bills 975 (1 ) 15 989 US agency bonds 5,813 (6 ) 38 5,845 Total $ 18,242 $ (7 ) $ 53 $ 18,288 December 31, 2023 Cost Accretion of Discount Fair Value Cash $ 157 $ – $ 157 Money market funds 12,434 – 12,434 US treasury bills 2,931 50 2,981 US agency bonds 3,938 21 3,959 Total $ 19,460 $ 71 $ 19,531

REVENUE

REVENUE	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
REVENUE	5. REVENUE The Company recognizes revenue in accordance with ASC No. 606. The Company generates revenues from engineering service contracts, license agreements and joint development agreements. The amount of revenue that the Company recognizes reflects the consideration it expects to receive in exchange for goods or services and such revenue is recognized when the Company satisfies a performance obligation by transferring the product or service to the customer. When the Company’s performance obligation is to grant a license, revenue is recognized either at a point in time (such as a right to use access The following table provides information about disaggregated revenue by primary geographical markets and timing of revenue recognition (in thousands): Schedule of disaggregated revenue by primary geographical markets and timing of revenue recognition Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Primary geographic markets North America $ 72 $ – $ 90 $ – Asia Pacific – – – – Total $ 72 $ – $ 90 $ – Timing of revenue recognition Products and services transferred at a point in time $ 50 $ – $ 50 $ – Products and services transferred over time 22 – 40 – Total $ 72 $ – $ 90 $ – Unbilled contracts receivable Timing of revenue recognition may differ from the timing of invoicing customers. Accounts receivable includes amounts billed and currently due from customers. Unbilled contracts receivable represents unbilled amounts expected to be received from customers in future periods, where the revenue recognized to date exceeds the amount billed, and the right to receive payment is subject to the underlying contractual terms. Unbilled contracts receivable amounts may not exceed their net realizable value and are classified as long-term assets if the payments are expected to be received more than one year from the reporting date. All unbilled contracts receivable as of December 31, 2023 were billed and received during the six months ended June 30, 2024. Deferred Revenue The Company records deferred revenue for customers that were issued invoices, but the Company has not yet recognized the revenue based on its revenue recognition policy. As of June 30, 2024, the Company has approximately $ 13

BASIC AND DILUTED LOSS PER SHAR

BASIC AND DILUTED LOSS PER SHARE	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
BASIC AND DILUTED LOSS PER SHARE	6. BASIC AND DILUTED LOSS PER SHARE Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of shares of common stock outstanding and the dilutive common stock equivalent shares outstanding during the period. The Company’s potentially dilutive common stock equivalent shares, which include incremental common shares issuable upon (i) the exercise of outstanding stock options and (ii) vesting of restricted stock units and restricted stock awards, are only included in the calculation of diluted net loss per share when their effect is dilutive. Since the Company has had net losses for all periods presented, all potentially dilutive securities are anti-dilutive. Accordingly, basic and diluted net loss per share are equal. The following potential common stock equivalents were not included in the calculation of diluted net loss per common share because the inclusion thereof would be anti-dilutive (in thousands): Schedule of anti-dilutive shares Six Months Ended June 30, 2024 2023 Stock Options 3,613 3,364 Unvested restricted stock 567 555 Total 4,180 3,919

LEASES

LEASES	6 Months Ended
	Jun. 30, 2024
Leases
LEASES	7. LEASES The Company accounts for leases over one year under ASC 842. Lease expense for the Company’s operating leases consists of the lease payments recognized on a straight-line basis over the lease term. Expenses for the Company’s financing leases consists of the amortization expenses recognized on a straight-line basis over the lease term and interest expense. The Company’s lease agreement for a tool used in the development and marketing of the Company’s technology established a monthly lease payment of $150,000 per month. The lease contains a provision for an annual adjustment of lease payments based on tool availability and usage during the preceding 12 months and the adjusted payment is calculated on August 1 of each year of the lease. Effective August 1, 2023, the lease payments for this tool were adjusted to $137,650 per month for the period August 1, 2023 through July 31, 2024. This adjustment to the lease payments also resulted in a reduction in the ROU and corresponding lease liability. Effective May 1, 2023, the Company leased an additional 404 square feet at its Tempe office location under an amendment to its current lease. The monthly rent payment increased from $1,277 per month to $2,365 per month and the increased rent under the amended lease is accounted for as a modification to the lease under ASC 842 at the time of commencement. 33,000 12,000 21,000 In December 2023, the Company entered into a lease agreement for a tool in Tempe, Arizona. The term of this lease is for 12 months beginning on January 1, 2024 for $87,000 per month. Since the lease term is not for more than one year and there are no extension provisions in the lease, the future lease payments are not included in the lease obligations on the Company’s condensed balance sheets. The Company terminated its office lease in Cambridge, Massachusetts as of March 31, 2023. The cost of the lease was $2,942 per month. The components of lease costs were as follows (in thousands): Schedule of lease costs Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Financing lease costs: Amortization of ROU assets $ 281 $ 290 $ 562 $ 581 Interest on lease liabilities 35 51 74 104 Total financing lease costs $ 316 $ 341 $ 636 $ 685 Operating lease costs: Fixed lease costs $ 65 $ 64 $ 131 $ 126 Short-term lease costs 261 244 522 541 Total operating lease costs $ 326 $ 308 $ 653 $ 667 Future minimum payments under non-cancellable leases as of June 30, 2024 were as follows (in thousands): Schedule of future minimum payments For the Year Ended December 31, Financing leases Operating leases Remaining 2024 $ 708 $ 121 2025 1,436 288 2026 478 24 Total future minimum lease payments 2,622 433 Less imputed interest (128 ) (40 ) Total lease liability $ 2,494 $ 393 The below table provides supplemental information and non-cash activity related to the Company’s operating and financing leases are as follows (in thousands): Schedule of supplemental information and non-cash activity Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating cash flow information: Cash paid for amounts included in the measurement of operating lease liabilities $ 61 $ 55 $ 171 $ 111 Cash paid for amounts included in the measurement of financing liabilities $ 330 $ 241 $ 549 $ 482 Non-cash activity: Right-of-use assets obtained in exchange for operating lease obligations $ – $ 33 $ – $ 33 The table above does not include short-term leases that are one-year or less. The weighted average remaining discount rate is 5.50 5.25 1.7 2.1

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
STOCK BASED COMPENSATION	8. STOCK BASED COMPENSATION In May 2017, the Company’s shareholders approved its 2017 Stock Incentive Plan (“2017 Plan”) after its 2007 Stock Incentive Plan (“2007 Plan”) had expired in March 2017. The 2017 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company’s common stock and for the grant of restricted and unrestricted shares. The 2017 Plan provides for the issuance of 3,750,000 2,000,000 1.4 million The following table summarizes the stock-based compensation expense recorded in the Company’s results of operations during the three and six months ended June 30, 2024 and 2023 for stock options and restricted stock granted under the Company’s incentive plans (in thousands): Schedule of stock-based compensation expense Three Months Ended June 30, Six Months Ended 2024 2023 2024 2023 Research and development $ 398 $ 372 $ 775 $ 700 General and administrative 525 570 1,108 1,095 Selling and marketing 64 88 128 162 Total $ 987 $ 1,030 $ 2,011 $ 1,957 As of June 30, 2024, there was approximately $ 7.8 million 2.9 The weighted average grant date fair value per share of the options granted under the Company’s Plans were $ 3.92 no 4.97 4.95 The following table summarizes stock option activity during the six months ended June 30, 2024 (in thousands except exercise prices and contractual terms): Schedule of stock option activity Number of Shares Weighted- Average Exercise Prices per Share Weighted- Remaining Contractual Term (In Years) Intrinsic Outstanding at January 1, 2024 3,369 $ 7.04 Granted 369 $ 6.44 Exercised (13 ) $ 6.60 Forfeited (68 ) $ 9.78 Expired (44 ) $ 14.61 Outstanding at June 30, 2024 3,613 $ 6.83 4.54 $ – Exercisable at June 30, 2024 2,943 $ 6.62 3.52 $ – During the six months ended June 30, 2024, the Company granted options under the 2017 and 2023 Plans to purchase approximately 369,000 1.8 million The Company issues restricted stock to employees, directors and consultants and estimates the fair value based on the closing price on the day of grant. The following table summarizes all restricted stock activity during the six months ended June 30, 2024 (in thousands except per share data): Schedule of restricted stock activity Number of Shares Weighted-Average Grant Date Fair Value per Share Outstanding at January 1, 2024 419 $ 9.21 Granted 342 $ 6.06 Forfeited (33 ) $ 8.00 Vested (161 ) $ 8.86 Outstanding non-vested shares at June 30 2024 567 $ 7.48 During the six months ended June 30, 2024, the Company granted approximately 342,000 2.1 million

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES Litigation, Claims and Assessments The Company may be subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of June 30, 2024, or through the date these financial statements have been issued.

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
EQUITY	10. EQUITY On April 28, 2024, the Company sold 2,247 4.45 10,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	11. SUBSEQUENT EVENTS Management has evaluated subsequent events and transactions through the date these financial statements were issued. Since June 30, 2024, the Company has issued approximately 206,000 additional shares through its ATM offering at an average price per share of $3.94 resulting in additional net proceeds of approximately $789,000

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 15, 2024.
Basis of Presentation of Unaudited Condensed Financial Information	Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the three and six months ended June 30, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and its results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2023 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC on February 15, 2024. These unaudited condensed financial statements should be read in conjunction with that report.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. Cash equivalents may be invested in money market funds or U.S. agency bonds. Cash and cash equivalents are carried at cost, which approximates their fair value. The Company's portfolio of short-term investments is comprised solely of U.S. treasury bills and agency bonds with maturities of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity requirements. These debt securities are classified as current assets in the condensed balance sheet and recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss). Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are reported in other income, net in the condensed statements of operations when incurred. Unrealized gains and losses are included in other comprehensive income (loss) on the condensed balance sheets.
Recent Accounting Standards	Recent Accounting Standards From time to time, new accounting standards are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. No new accounting standards issued or effective during the period ended June 30, 2024 have had or are expected to have a significant impact on the Company’s financial statements.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of fair value measurements	Schedule of fair value measurements June 30, 2024 Cost Unrealized Gain/(Loss) Accretion of Discount Fair Value Cash $ 86 $ – $ – $ 86 Money market funds 11,368 – – 11,368 US treasury bills 975 (1 ) 15 989 US agency bonds 5,813 (6 ) 38 5,845 Total $ 18,242 $ (7 ) $ 53 $ 18,288 December 31, 2023 Cost Accretion of Discount Fair Value Cash $ 157 $ – $ 157 Money market funds 12,434 – 12,434 US treasury bills 2,931 50 2,981 US agency bonds 3,938 21 3,959 Total $ 19,460 $ 71 $ 19,531

REVENUE (Tables)

REVENUE (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenue by primary geographical markets and timing of revenue recognition	Schedule of disaggregated revenue by primary geographical markets and timing of revenue recognition Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Primary geographic markets North America $ 72 $ – $ 90 $ – Asia Pacific – – – – Total $ 72 $ – $ 90 $ – Timing of revenue recognition Products and services transferred at a point in time $ 50 $ – $ 50 $ – Products and services transferred over time 22 – 40 – Total $ 72 $ – $ 90 $ –

BASIC AND DILUTED LOSS PER SH_2

BASIC AND DILUTED LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of anti-dilutive shares	Schedule of anti-dilutive shares Six Months Ended June 30, 2024 2023 Stock Options 3,613 3,364 Unvested restricted stock 567 555 Total 4,180 3,919

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2024
Leases
Schedule of lease costs	Schedule of lease costs Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Financing lease costs: Amortization of ROU assets $ 281 $ 290 $ 562 $ 581 Interest on lease liabilities 35 51 74 104 Total financing lease costs $ 316 $ 341 $ 636 $ 685 Operating lease costs: Fixed lease costs $ 65 $ 64 $ 131 $ 126 Short-term lease costs 261 244 522 541 Total operating lease costs $ 326 $ 308 $ 653 $ 667
Schedule of future minimum payments	Schedule of future minimum payments For the Year Ended December 31, Financing leases Operating leases Remaining 2024 $ 708 $ 121 2025 1,436 288 2026 478 24 Total future minimum lease payments 2,622 433 Less imputed interest (128 ) (40 ) Total lease liability $ 2,494 $ 393
Schedule of supplemental information and non-cash activity	Schedule of supplemental information and non-cash activity Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating cash flow information: Cash paid for amounts included in the measurement of operating lease liabilities $ 61 $ 55 $ 171 $ 111 Cash paid for amounts included in the measurement of financing liabilities $ 330 $ 241 $ 549 $ 482 Non-cash activity: Right-of-use assets obtained in exchange for operating lease obligations $ – $ 33 $ – $ 33

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense	Schedule of stock-based compensation expense Three Months Ended June 30, Six Months Ended 2024 2023 2024 2023 Research and development $ 398 $ 372 $ 775 $ 700 General and administrative 525 570 1,108 1,095 Selling and marketing 64 88 128 162 Total $ 987 $ 1,030 $ 2,011 $ 1,957
Schedule of stock option activity	Schedule of stock option activity Number of Shares Weighted- Average Exercise Prices per Share Weighted- Remaining Contractual Term (In Years) Intrinsic Outstanding at January 1, 2024 3,369 $ 7.04 Granted 369 $ 6.44 Exercised (13 ) $ 6.60 Forfeited (68 ) $ 9.78 Expired (44 ) $ 14.61 Outstanding at June 30, 2024 3,613 $ 6.83 4.54 $ – Exercisable at June 30, 2024 2,943 $ 6.62 3.52 $ –
Schedule of restricted stock activity	Schedule of restricted stock activity Number of Shares Weighted-Average Grant Date Fair Value per Share Outstanding at January 1, 2024 419 $ 9.21 Granted 342 $ 6.06 Forfeited (33 ) $ 8.00 Vested (161 ) $ 8.86 Outstanding non-vested shares at June 30 2024 567 $ 7.48

LIQUIDITY AND MANAGEMENT PLANS

LIQUIDITY AND MANAGEMENT PLANS (Details Narrative)	3 Months Ended	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Cash, cash equivalents and short-term investments	$ 18,300,000	$ 18,300,000
Working capital	$ 15,800,000	$ 15,800,000
ATM [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued new, shares | shares	669,000	1,200,000
Average price per share | $ / shares	$ 3.82	$ 5.66
Proceeds from sale of stock, value	$ 2,400,000	$ 6,400,000
Remaining offering capacity	$ 23,100,000	$ 23,100,000

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Fair Value, Inputs, Level 1 [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost	$ 18,242	$ 19,460
Unrealized Gain/(Loss)	(7)
Accretion of Discount	53	71
Fair Value	18,288	19,531
Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost	86	157
Unrealized Gain/(Loss)	0
Accretion of Discount	0	0
Fair Value	86	157
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost	11,368	12,434
Unrealized Gain/(Loss)	0
Accretion of Discount	0	0
Fair Value	11,368	12,434
US treasury bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost	975	2,931
Unrealized Gain/(Loss)	(1)
Accretion of Discount	15	50
Fair Value	989	2,981
US agency bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost	5,813	3,938
Unrealized Gain/(Loss)	(6)
Accretion of Discount	38	21
Fair Value	$ 5,845	$ 3,959

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 72	$ 0	$ 90	$ 0
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue	50	0	50	0
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue	22	0	40	0
North America [Member]
Disaggregation of Revenue [Line Items]
Revenue	72	0	90	0
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 0	$ 0	$ 0	$ 0

REVENUE (Details Narrative)

REVENUE (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Deferred revenue	$ 13	$ 0

BASIC AND DILUTED LOSS PER SH_3

BASIC AND DILUTED LOSS PER SHARE (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive shares	4,180	3,919
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive shares	3,613	3,364
Unvested restricted stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive shares	567	555

LEASES (Details - Lease costs)

LEASES (Details - Lease costs) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Financing lease costs:
Amortization of ROU assets	$ 281	$ 290	$ 562	$ 581
Interest on lease liabilities	35	51	74	104
Total financing lease costs	316	341	636	685
Operating lease costs:
Fixed lease costs	65	64	131	126
Short-term lease costs	261	244	522	541
Total operating lease costs	$ 326	$ 308	$ 653	$ 667

LEASES (Details - Minimum lease

LEASES (Details - Minimum lease payments) $ in Thousands	Jun. 30, 2024 USD ($)
Operating Leases [Member]
Debt Instrument [Line Items]
Remaining 2024	$ 121
2025	288
2026	24
Total future minimum lease payments	433
Less imputed interest	(40)
Total lease liability	393
Financing Leases [Member]
Debt Instrument [Line Items]
Remaining 2024	708
2025	1,436
2026	478
Total future minimum lease payments	2,622
Less imputed interest	(128)
Total lease liability	$ 2,494

LEASES (Details - Cash flow eff

LEASES (Details - Cash flow effect) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating cash flow information:
Cash paid for amounts included in the measurement of operating lease liabilities	$ 61	$ 55	$ 171	$ 111
Cash paid for amounts included in the measurement of financing liabilities	330	241	549	482
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	$ 0	$ 33	$ 0	$ 33

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)		6 Months Ended	12 Months Ended
	May 01, 2023	Jun. 30, 2024	Dec. 31, 2023
Lessee operating lease description	Effective May 1, 2023, the Company leased an additional 404 square feet at its Tempe office location under an amendment to its current lease. The monthly rent payment increased from $1,277 per month to $2,365 per month and the increased rent under the amended lease is accounted for as a modification to the lease under ASC 842 at the time of commencement.		In December 2023, the Company entered into a lease agreement for a tool in Tempe, Arizona. The term of this lease is for 12 months beginning on January 1, 2024 for $87,000 per month. Since the lease term is not for more than one year and there are no extension provisions in the lease, the future lease payments are not included in the lease obligations on the Company’s condensed balance sheets.
Right-of-use asset		$ 401,000	$ 517,000
Short-term operating lease liability		256,000	264,000
Long-term operating lease liability		$ 137,000	$ 295,000
Lessee, operating lease terminate description		The Company terminated its office lease in Cambridge, Massachusetts as of March 31, 2023. The cost of the lease was $2,942 per month.
Weighted average remaining discount rate for operating leases		5.50%
Weighted average remaining discount rate for financing leases		5.25%
Weighted average lease term for operating lease		1 year 8 months 12 days
Weighted average lease term for financing lease		2 years 1 month 6 days
Tempe AZ Office [Member]
Right-of-use asset	$ 33,000
Short-term operating lease liability	12,000
Long-term operating lease liability	$ 21,000

STOCK BASED COMPENSATION (Detai

STOCK BASED COMPENSATION (Details - Compensation expense) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated stock-based compensation	$ 987	$ 1,030	$ 2,011	$ 1,957
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated stock-based compensation	398	372	775	700
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated stock-based compensation	525	570	1,108	1,095
Selling And Marketing [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated stock-based compensation	$ 64	$ 88	$ 128	$ 162

STOCK BASED COMPENSATION (Det_2

STOCK BASED COMPENSATION (Details - Stock option activity) - Equity Option [Member] $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, Beginning balance | shares	3,369
Options outstanding, weighted average exercise prices per share, Beginning balance | $ / shares	$ 7.04
Number of options granted | shares	369
Options granted, weighted average exercise prices per share | $ / shares	$ 6.44
Number of options exercised | shares	(13)
Options exercised, weighted average exercise prices per share | $ / shares	$ 6.60
Number of options forfeited | shares	(68)
Options forfeited, weighted average exercise prices per share | $ / shares	$ 9.78
Number of options expired | shares	(44)
Options expired, weighted average exercise prices per share | $ / shares	$ 14.61
Number of options outstanding, Ending balance | shares	3,613
Options outstanding, weighted average exercise prices per share, Ending balance | $ / shares	$ 6.83
Options outstanding, weighted average remaining contractual term	4 years 6 months 14 days
Options outstanding, intrinsic value | $	$ 0
Options exercisable | shares	2,943
Options exercisable, weighted average exercise prices per share | $ / shares	$ 6.62
Options exercisable, weighted average remaining contractual term	3 years 6 months 7 days
Options exercisable, intrinsic value | $	$ 0

STOCK BASED COMPENSATION (Det_3

STOCK BASED COMPENSATION (Details - Restricted stock) - Restricted Stock [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of outstanding non-vested restricted stock, Beginning balance | shares	419
Outstanding non-vested restricted stock, weighted average grant date fair value per share, Beginning balance | $ / shares	$ 9.21
Number of restricted stock granted | shares	342
Restricted stock granted, weighted average grant date fair value per share | $ / shares	$ 6.06
Number of restricted stock, forfeited | shares	(33)
Restricted stock forfeited, weighted average grant date fair value per share | $ / shares	$ 8
Number of restricted stock, vested | shares	(161)
Restricted stock vested, weighted average grant date fair value per share | $ / shares	$ 8.86
Number of outstanding non-vested restricted stock, Ending balance | shares	567
Outstanding non-vested restricted stock, weighted average grant date fair value per share, Ending balance | $ / shares	$ 7.48

STOCK BASED COMPENSATION (Det_4

STOCK BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for grant	1,400,000		1,400,000
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense	$ 7,800,000		$ 7,800,000
Unrecognized compensation weighted average period			2 years 10 months 24 days
Weighted average grant date fair value per share	$ 3.92	$ 0	$ 4.97	$ 4.95
Options granted			369,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period			342,000
2017 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized for issuance	3,750,000		3,750,000
2017 Plan [Member] | Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted			369,000
Fair value of options granted			$ 1,800,000
2023 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized for issuance	2,000,000		2,000,000
2023 Plan [Member] | Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted			369,000
Fair value of options granted			$ 1,800,000
2023 Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value of options granted			$ 2,100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period			342,000

EQUITY (Details Narrative)

EQUITY (Details Narrative) - Chief Executive Officer [Member]	Apr. 28, 2024 USD ($) $ / shares shares
Stock Issued During Period, Shares, New Issues | shares	2,247
Sale of Stock, Price Per Share | $ / shares	$ 4.45
Proceeds from Issuance of Common Stock | $	$ 10,000